Farmas USA

La sorpresa de la manana esta farma va 18% arriba AUXL, espero no venga a robarle el show a EXEL y SNSS

Pues entonces fuimos los únicos palurd@s que compramos a ese precio...jaja

A ver si recuperamos!!

Saludos

Tu tb,es que no tenemos paciencia...

S2

SNTA otro +10% en pre-market...vaya 3 dias que lleva...suerte que compre el miercoles antes del 1r arreón..ya dije que era la gran tapada de ASCO...mucho recorrido aun...¿alguien se apunta?

Parece que las 3 presentaciones de esta mañana estan convenciendo....

Updated Phase 1 results – Ganetespib/docetaxel combination in solid tumors

“A Phase 1 and Pharmacokinetic Study of Ganetespib (STA-9090), a Heat Shock Protein 90 Inhibitor, in Combination with Docetaxel in Subjects with Advanced Solid Tumor Malignancies.” (Abstract: 3094) – June 4, 8:00 a.m. – 12:00 pm CT; General Poster Session- Developmental Therapeutics. Poster Board: 19D, S Hall A2.

Presenter: John S. Kauh, M.D. - Winship Cancer Institute of Emory University, Atlanta, GA

Ganetespib activity in ALK- and ROS-driven cancer models

"Preclinical Activity of the Hsp90 Inhibitor, Ganetespib, in ALK- and ROS1-Driven Cancers.” (Abstract #3090) – June 4, 8:00 a.m. – 12:00 pm CT; General Poster Session- Developmental Therapeutics - Experimental Therapeutics. Poster Board: 18H, S Hall A2.

Presenter: David Proia, Ph.D. – Synta Pharmaceuticals Corp.

Ocular toxicity profiles of Hsp90 inhibitors

"Associating Retinal Drug Exposure and Retention with the Ocular Toxicity Profiles of Hsp90 Inhibitors." (Abstract #3086) – June 4, 8:00 a.m. – 12:00 pm CT; General Poster Session- Developmental Therapeutics. Poster Board: 18D, S Hall A2.

Presenter: Dan Zhou, M.D., M.M. – Synta Pharmaceuticals Corp.

Mirad que dicen de nuestra Niña:

5 Biotech Stocks That Could Be Included In The Russell 2000
June 4, 2012  | 1 comment  |  includes: AGEN, ANIK, IMUC, OMER, THLD

(5 Reservas de biotecnología que podrían incluirse en el Russell 2000
04 De junio de 2012 | 1 comentario | incluye: AGEN, ANIK, IMUC, OMER, THLD)

On May 31st, the Russell 2000 began to rebalance its holdings to determine which securities would be added to its index and which companies would be removed. To be included in the Russell 2000 is a great accomplishment for small companies and a provider of great opportunity. This index is often the benchmark for mutual funds with small cap strategies. Those investing in it are often required to purchase each security within the index. Due to the sheer size of the Russell 2000, it can provide significant buying pressure to all companies involved, even the ones that are the smallest in terms of weighted average in the index.

The average company in the Russell 2000 has a market cap of around $500 million. Each company in the index is required to have a stock price of at least $1 and a market capitalization of over $110 million (which was the smallest company included following the previous rebalancing). With that being said, let's take a look at five biotechnology companies that have returned large gains and could now be included in the index. The preliminary list will be announced on June 8th, but there is no doubt that investors will be trying to determine which stocks could be included due to the benefit of its exposure.

Threshold Pharmaceuticals (THLD) has been the best performer of 2012 with a 470% gain. The company began 2012 with a market cap of under $70 million but is now valued at nearly $400 million. The reason is because of a global agreement with Merck KGaA (MKGAF.PK) to co-develop and commercialize its small molecule hypoxia-targeted drug, TH-302. Soon after the agreement, THLD announced that its Phase IIb study met its primary endpoint with a 63% improvement in progression-free survival, creating even more optimism for this budding biotech.

As a result of Threshold's recent developments, its ability to maintain its valuation, and its potential, I expect its inclusion into the index. In fact, if the company is not included, it would most likely be a disappointment. In any case, the company has very significant institutional ownership. According to Reuters, 50.10% of its shares are held by institutions with about 24.66% being held by insiders, a strong show of support for the company from within.

5 Biotech Stocks That Could Be Included In The Russell 2000

buah, el premarket está más seco que la mojama. No se mueven ni las hojas de los árboles...

y GALE en premarket con un 15% subida